This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.
UK-RISN-230338. Date of preparation May 2024.
Find out more about the efficacy of SKYRIZI
Explore the durability of response with SKYRIZI through clinical trials and long-term data in psoriasis and psoriatic arthritis. Start by selecting a study from the menu below.
LONG-TERM DATA
HEAD-TO-HEAD TRIALS
SKYRIZI IN PsA
HEAD-TO-HEAD TRIALS: SKYRIZI vs Secukinumab (IMMerge)
Superior efficacy in psoriasis with fewer injections vs secukinumab at 52 Weeks3,5
87% of SKYRIZI patients achieved PASI 90 at Week 52 after 5 doses compared with 57% of secukinumab patients after 16 doses†3,5
Adapted from Warren RB, et al. 2020.
Data from IMMerge, a Phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded active-comparator study in adult patients with moderate to severe plaque psoriasis.
NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index. P-values for comparison vs secukinumab: *P<0.001 multiplicity controlled.
Data assessed for intent-to-treat population. Adjusted difference CI values: 96.25% at Week 16 and 95%; P values calculated from the Cochran-Mantel-Haenszel test, stratified by weight (≤100 kg vs >100 kg) and prior systemic biologic use for psoriasis.
†Each dose for SKYRIZI given as two 75-mg subcutaneous injections, each dose for secukinumab given as two 150-mg subcutaneous injections.
SKYRIZI demonstrated superiority at Week 52 across primary and all ranked secondary endpoints.
Co-primary endpoints were met:
- Non-inferiority of SKYRIZI vs secukinumab at Week 16 (PASI 90: 74% vs 66%)
- Superiority of SKYRIZI vs secukinumab at Week 52 (PASI 90: 87% vs 57%, P<0.001)
66% of SKYRIZI patients achieved PASI 100 at Week 52 after 5 doses compared with 40% of secukinumab patients after 16 doses†3,5
Adapted from Warren RB, et al. 2020.
Data from IMMerge, a phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded active-comparator study in adult patients with moderate to severe plaque psoriasis.
NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index. P-values for comparison vs secukinumab: *P<0.001 multiplicity controlled.
Data assessed for intent-to-treat population. Adjusted difference CI set at 95%; P values calculated from the Cochran-Mantel-Haenszel test, stratified by weight (≤100 kg vs >100 kg) and prior systemic biologic use for psoriasis.
†Each dose for SKYRIZI given as two 75-mg subcutaneous injections, each dose for secukinumab given as two 150-mg subcutaneous injections.
All ranked secondary endpoints were met, including statistically significant superiority of SKYRIZI vs secukinumab at Week 52 (PASI 100: 66% vs 40%, P<0.001). Co-primary endpoints were met: PASI 90 at Week 16 (non-inferiority) and PASI 90 at Week 52 (superiority).
IMMerge Study Design
A Phase III, global, multicentre, randomised, open-label, efficacy assessor-blinded, active comparator study to evaluate the safety and efficacy of risankizumab vs secukinumab in adults with moderate to severe plaque psoriasis.
Adapted from Warren RB, et al. 2020.
A total of 327 subjects were randomised 1:1 to SKYRIZI (n=164) (150 mg), given as two 75-mg subcutaneous injections at baseline, 4 weeks later, and every 12 weeks thereafter, or secukinumab (n=163) (300 mg) given as two 150-mg subcutaneous injections, at baseline, weeks 1, 2, 3, and 4, and then every 4 weeks thereafter.
PASI, Psoriasis Area and Severity Index.
Co-primary endpoints
- PASI 90 at Week 52 (superiority): Proportion of patients who achieved PASI 90 response at Week 52 vs secukinumab.
- PASI 90 at Week 16 (non-inferiority): Proportion of patients who achieved PASI 90 response at Week 16 vs secukinumab.
Co-primary endpoints were met.
Ranked secondary endpoints
- PASI 100 at Week 52 vs secukinumab
- PASI 75 at Week 52 vs secukinumab
- sPGA 0/1 at Week 52 vs secukinumab
All ranked secondary endpoints were met.
PASI, Psoriasis Severity Index; sPGA, static Physicians’ Global Assessment.
IMMerge baseline demographics3,5
Key demographics and baseline characteristics were generally balanced between treatment groups and consistent with the pivotal UltIMMa-1 and UltIMMa-2 trials.3
Adapted from Warren RB, et al. 2020.
SD, standard deviation; sPGA, static Physician Global Assessment; PASI, Psoriasis and Severity Index; PsO, psoriasis.
Consistent safety profile through to 52 Weeks in the IMMerge trial3
Adapted from Warren RB, et al. 2020.
*Defined as AEs occurring with an onset within 20 weeks after the last dose of study drug administration.
AE, adverse event; MACE, major adverse cardiovascular event, NMSC, non-melanoma skin cancer; TEAEs, treatment-emergent adverse events.
Featured content
More expert perspectives
View expert perspectives on SKYRIZI’s efficacy data, dosing regimen and safety profile.
UK-RISN-240178. Date of preparation May 2024.
References
- Reich K, et al. Lancet 2019; 394: 576-586.
- Gordon KB, et al. Lancet 2018; 392: 650-661.
- Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
- SKYRIZI: Summary of Product Characteristics.
- Warren RB, et al. Br J Dermatol 2021; 185: 50-59.
UK-RISN-240142. Date of preparation: May 2024.
